重新考虑老年质母细胞瘤的治疗缓解:多中心真实世界队列的经验教训
Orit Furman1,2, Eva Falah3, Inbar Dvir2,4
1Neuro-Radiotherapy Unit, Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Neuro-oncology advances
|March 4, 2026
概括
质母细胞瘤的老年患者可能会从标准治疗中受益,随着年龄的增长,健康指导决策. 现实世界的数据显示,化学放射治疗为符合条件的老年人提供了最长的生存期.
科学领域:
- 神经瘤学神经瘤学
- 老年瘤学 老年瘤学
- 临床试验分析临床试验分析
背景情况:
- 老年质母细胞瘤 (GBM) 患者面临着不良预后和高治疗毒性.
- 降级方案是常见的,通常基于MGMT促进剂甲基化状态.
- 老年人GBM治疗的现实结果和分子细节被低估了.
研究的目的:
- 评估老年GBM患者不同治疗策略的现实结果.
- 为了确定影响这一群体生存的因素.
- 为了比较各种手术后治疗的疗效和毒性.
主要方法:
- 在2009-2023年期间接受治疗的573名老年GBM患者 (≥65岁) 的回顾性分析.
- 治疗方法的比较:化疗辐射疗法 (CRT),特莫索洛米德 (TMZ) 单一疗法,单独放射疗法 (RT) 和最佳支持性护理.
- 使用卡普兰-梅尔和日志等级测试的生存分析,分析MGMT状态和卡诺夫斯基性能状态 (KPS).
主要成果:
- 化疗放射治疗 (CRT) 显示最长的平均整体存活期 (mOS) 为14个月,而TMZ/RT治疗为8个月,支持性治疗为2个月.
- 在MGMT甲基化患者中,CRT mOS为23个月,而TMZ为8个月.
- 较高的KPS,较年轻的年龄和手术切除预测了更长的生存时间;TMZ毒性低.
结论:
- 健身的老年GBM患者可以从标准的全剂量治疗中受益.
- 治疗决策应优先考虑功能和临床健康,而不是时间年龄.
- 整合临床和功能因素对于管理老年GBM患者至关重要.
相关概念视频
02:56Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:15Drug Dosing: Geriatric Patients
400
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
400
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
358
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
358
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
376
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
376